Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2024)

Solid Biosciences' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $211.8 million for Q3 2024.

  • For Q3 2024, Liabilities and Shareholders Equity rose 14.67% year-over-year to $211.8 million; the TTM value through Dec 2024 reached $691.5 million, down 11.8%, while the annual FY2023 figure was $164.9 million, 36.62% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2024 was $211.8 million at Solid Biosciences, down from $231.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $285.3 million in Q1 2021 and bottomed at $40.5 million in Q3 2020.
  • The 5-year median for Liabilities and Shareholders Equity is $208.5 million (2022), against an average of $195.4 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 69.05% in 2020 before it skyrocketed 514.51% in 2021.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $171.2 million in 2020, then soared by 35.76% to $232.4 million in 2021, then rose by 11.99% to $260.3 million in 2022, then plummeted by 36.62% to $164.9 million in 2023, then rose by 28.43% to $211.8 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Liabilities and Shareholders Equity are $211.8 million (Q3 2024), $231.0 million (Q2 2024), and $248.7 million (Q1 2024).